Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Innate-pharma.com image

News from innate-pharma.com

All of today’s top news stories from Innate-pharma.com. Get the full analysis behind how media bias impacts breaking news.

We’ve aggregated 11 of Innate-pharma.com’s headlines and news stories over the past 3 months.

We’ve assigned a media bias rating of unknown to Innate-pharma.com. You can read more about our methodology here.

We’ve assigned a rating of Unknown factuality to Innate-pharma.com. You can read more about how we’ve determined Innate-pharma.com’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.

Information about Innate-pharma.com

Where is Innate-pharma.com located?Innate-pharma.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Innate-pharma.com News

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

Artificial Intelligence · Marseille

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

100% Center coverage: 2 sources

MARSEILLE, France--(BUSINESS WIRE)--Jul 4, 2025-See the Story

Outcome of Innate Pharma’s 2025 Annual General Meeting

Outcome of Innate Pharma’s 2025 Annual General Meeting Fri, 05/23/2025 - 07:00 Press release in English 232.75 KB Communiqué de presse en français 168.95 KB helene Thu, 05/22/2025Marseille · Marseille Read Article

Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides

Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides Fri, 05/23/2025 - 07:00 Press Release in English 230.44 KB Communiqué de presse en français 188.74 KB mathilde Thu, 05/22/2025Marseille · Marseille Read Article

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

100% Left coverage: 1 sources

MARSEILLE, France--(BUSINESS WIRE)--May 15, 2025-Marseille · Marseille See the Story

Velo3D Announces First Quarter 2025 Financial Results

59% Center coverage: 106 sources

Revenue of $9.3 millionGross margin of 7.5%Backlog of $18 million as of March 31, 2025Reaffirms expectation for 2025 annual revenue growth of more than 30%Reaffirms expectation to be EBITDA positive in the first half of 2026Voting See the Story

Innate Pharma announces conference call and webcast for Q1 2025 business update

Innate Pharma announces conference call and webcast for Q1 2025 business update Tue, 05/06/2025 - 07:00 Press release in English 228.44 KB Communiqué de presse en français 180.1 KB helene Mon, 05/05/2025Marseille · Marseille Read Article

€15M Sanofi Investment Powers Innate Pharma's Pipeline Growth: Key Partnership Expands

Fresh €15M capital injection strengthens Innate-Sanofi partnership. Strategic investment extends cash runway for pipeline development. See growth strategy.Marseille · Marseille See the Story

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

100% Center coverage: 1 sources

MARSEILLE, France--(BUSINESS WIRE)--Apr 23, 2025-Marseille · Marseille See the Story

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

100% Left coverage: 1 sources

MARSEILLE, France--(BUSINESS WIRE)--Apr 16, 2025-Cricket · Marseille See the Story

You've scrolled to the bottom of the feed, there are no more stories.

Breaking News Topics Related to Innate-pharma.com

Our use of cookiesCookie policy

Unlike other news sites, we do not share or sell your data to third-parties for targeted ads. In fact, the Ground News application and website do not run any ads at all. Our application and website use cookies and similar technologies to personalize content we deliver to you and also allows us to improve your usage of our platform through analytics. These cookies help us provide the best experience possible. Learn more about cookies and preference selection here.

By continuing to use our application or website, you agree to our Terms of Service and Privacy Policy.